Charles Homcy, M.D.
Charles Homcy joined Third Rock Ventures in 2010 and focuses on the formation of companies discovering and developing novel therapeutic approaches. He brings significant experience building and leading successful biotech companies and has played an integral role in the launching and building of several portfolio companies:
- Board member of Ambys Medicines
- Board member and co-founder of Global Blood Therapeutics
- Board member of Pliant Therapeutics
- Former board member of CytomX
- Goldfinch Bio
- Former board member and former interim chief executive officer of MyoKardia
- Relay Therapeutics
- Interim chief executive officer of Maze Therapeutics
Prior to Third Rock, Charles co-founded Portola Pharmaceuticals and served as president and chief executive officer. Earlier, he served as president of research and development at Millennium, following Millennium's acquisition of COR Therapeutics in 2002. Charles joined COR in 1995 as executive vice president of research and development and served as a director of the company from 1998 to 2002. He has been a clinical professor of medicine at the University of California, San Francisco Medical School and attending physician at the San Francisco VA Hospital since 1997. He was previously president of the medical research division of American Cyanamid-Lederle Laboratories, a division of Wyeth. Charles is a board member of Portola. He received his A.B. and M.D. from Johns Hopkins University where he presently serves on the board of trustees.
Charles and his wife have been avid wild mushroom foragers for nearly 30 years.